Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Arisaph Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Arisaph Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Arisaph Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Arisaph Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Arisaph Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Arisaph Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Arisaph Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Arisaph Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Arisaph Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Arisaph Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Arisaph Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arisaph Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Arisaph Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Arisaph Pharmaceuticals, Inc. Snapshot 5 Arisaph Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Arisaph Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Arisaph Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Arisaph Pharmaceuticals, Inc. - Pipeline Products Glance 10 Arisaph Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10 Phase II Products/Combination Treatment Modalities 10 Phase I Products/Combination Treatment Modalities 11 Arisaph Pharmaceuticals, Inc. - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 Arisaph Pharmaceuticals, Inc. - Drug Profiles 14 ARI-3037MO 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 ARI-2243 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 ARI-1778 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ARI-2408 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ARI-3996 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ARI-4175 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Peptides to Agonize GLP-1 for Type II Diabetes 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Tumor Activated Pro-Soft Drugs 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Vaccine for Cancer 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Inhibit Lipase for Atherosclerosis 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Arisaph Pharmaceuticals, Inc. - Pipeline Analysis 27 Arisaph Pharmaceuticals, Inc. - Pipeline Products by Target 27 Arisaph Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 28 Arisaph Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 29 Arisaph Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 30 Arisaph Pharmaceuticals, Inc. - Recent Pipeline Updates 31 Arisaph Pharmaceuticals, Inc. - Dormant Projects 32 Arisaph Pharmaceuticals, Inc. - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables Arisaph Pharmaceuticals, Inc., Key Information 5 Arisaph Pharmaceuticals, Inc., Key Facts 5 Arisaph Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7 Arisaph Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8 Arisaph Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9 Arisaph Pharmaceuticals, Inc. - Phase II, 2014 10 Arisaph Pharmaceuticals, Inc. - Phase I, 2014 11 Arisaph Pharmaceuticals, Inc. - Preclinical, 2014 12 Arisaph Pharmaceuticals, Inc. - Discovery, 2014 13 Arisaph Pharmaceuticals, Inc. - Pipeline by Target, 2014 27 Arisaph Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 28 Arisaph Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 29 Arisaph Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 30 Arisaph Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 31 Arisaph Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.